MaxCyte to delist shares from London AIM, maintains Nasdaq listing

MaxCyte (NASDAQ:MXCT) is delisting its common stock from the London Stock Exchange's AIM market, effective Thursday, while maintaining its primary listing on the Nasdaq Global Select Market. This move, approved by shareholders, occurs amidst significant stock pressure, with shares down over 46% in six months. Despite reporting Q1 2025 revenue of $10.4 million and EPS of -$0.10, both exceeding analyst forecasts, BTIG adjusted its price target to $5.00 from $6.00, citing macroeconomic and biopharmaceutical funding uncertainties, though maintaining a Buy rating. MaxCyte reaffirmed its 2025 revenue guidance, emphasizing its focus on the cell and gene therapy market.

Analysis

MaxCyte, Inc. is executing a strategic consolidation of its stock listing onto the Nasdaq Global Select Market by delisting from London's AIM exchange. This corporate action occurs against a challenging market backdrop, with the company's stock having declined over 46% in the past six months to trade near its 52-week low. Despite this significant stock price pressure, the company's operational performance shows signs of strength. For its first quarter of 2025, MaxCyte reported revenue of $10.4 million and an EPS of -$0.10, surpassing analyst forecasts of $9.05 million and -$0.11, respectively. In a mixed signal, a BTIG analyst maintained a Buy rating but reduced the price target to $5.00 from $6.00, citing macroeconomic challenges and biopharmaceutical funding uncertainties as key headwinds. The company's management has reaffirmed its full-year 2025 revenue guidance, signaling confidence in its strategic initiatives within the cell and gene therapy market. Shareholders have endorsed the company's direction by approving the AIM delisting and an increase of 2,950,000 authorized shares for its equity incentive plan, a move that could lead to future dilution.

Key Decisions for Investors

• Investors should weigh the company's strong Q1 operational performance, marked by a revenue and EPS beat, against the significant stock depreciation and the cautious analyst outlook driven by macroeconomic factors.
• The delisting from London's AIM market simplifies the company's capital structure, but the concurrent approval of 2.95 million additional shares for the equity incentive plan introduces a potential dilution risk that must be factored into valuation models.
• Monitor biopharmaceutical industry funding trends closely, as the analyst's price target cut to $5.00, despite a maintained Buy rating, indicates that external market conditions are a primary risk factor for MaxCyte's valuation recovery.